AdAlta (1AD) Investor Presentation summary

Strategic vision and business model

• Focuses on commercializing next-generation cellular immunotherapies for solid cancers using an "East to West" strategy, in-licensing Asian assets and advancing them in Western markets for value creation.

• Leverages Australia's cost-effective manufacturing and clinical trial environment, with a capital-light, scalable model and frequent value inflection points.

• Monetizes additional assets in fibrosis (AD-214) and malaria (WD-34), seeking partners for further development and commercialization.

• Targets rapid asset turnover, aiming for one new clinical trial per year and systematic pipeline expansion.

• Experienced team with global reach and established networks to execute the growth strategy.

Market opportunity and industry trends

• CAR-T cell therapy is revolutionizing cancer treatment, with high response rates and a projected $20B market by 2028, now expanding into solid tumors.

• China is a major driver of biopharma innovation, with 61% of global cellular immunotherapy trials in Asia Pacific and 30% of big pharma deals involving Chinese biotech.

• Barriers for Asian innovations to reach Western markets include regulatory, capital, and data transfer challenges, which the strategy aims to overcome.

• T cell therapies for solid cancers represent a less competitive, high-growth segment with significant unmet need.

Asset portfolio highlights

• Armoured X-CAR-T: First-in-class, anti-PD1 secreting CAR-T for multiple solid cancers, with superior response in mesothelioma and rapid, virus-free manufacturing.

• Y-CAR-T: Novel target CAR-T with safety switch, multi-dosing, and both systemic and local administration, showing strong preclinical and early clinical results.

• AD-214: First-in-class anti-fibrotic protein for diseases like IPF, with Phase I complete, strong IP, and out-licensing efforts underway.

• WD-34: World-first pan-species anti-malarial i-body, targeting a $990M market, with potential for long-acting prophylaxis and new vaccine strategies.